Inside J&J’s Latam COVID vaccine trial, a rush to recruit is followed by disappointment
By Aislinn Laing SANTIAGO (Reuters) - Earlier this month, Johnson & Johnson (NYSE:JNJ) abruptly called for an end to enrollment in its coronavirus vaccine trial and told scientists from six Latin American countries to wrap up their work within 48 hours, two researchers told Reuters. The halt was due to J&J's decision, announced...
Continue reading